Evidence map›Paper›PMID 33995109›Full record

ArticleFrontiers in pharmacology2021

Alcohol Co-Administration Changes Mephedrone-Induced Alterations of Neuronal Activity.

Milo Grotell, Bjørnar den Hollander, Aaro Jalkanen, Essi Törrönen, Jouni Ihalainen, Elena de Miguel, Mateusz Dudek, Mikko I Kettunen, Petri Hyytiä, Markus M Forsberg and 2 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in pharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.1field-weighted citation impact, top 63% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Milo GrotellDepartment of Pharmacology, Faculty of Medicine, University of Helsinki, Helsinki, Finland.
Bjørnar den HollanderDepartment of Pharmacology, Faculty of Medicine, University of Helsinki, Helsinki, Finland.
Aaro JalkanenSchool of Pharmacy, Faculty of Health Sciences, University of Eastern Finland, Kuopio, Finland.
Essi TörrönenDepartment of Pharmacology, Faculty of Medicine, University of Helsinki, Helsinki, Finland.
Jouni IhalainenSchool of Pharmacy, Faculty of Health Sciences, University of Eastern Finland, Kuopio, Finland.
Elena de MiguelDepartment of Pharmacology, Faculty of Medicine, University of Helsinki, Helsinki, Finland.
Mateusz DudekDepartment of Pharmacology, Faculty of Medicine, University of Helsinki, Helsinki, Finland.
Mikko I KettunenKuopio Biomedical Imaging Unit, A.I. Virtanen Institute for Molecular Sciences, Faculty of Health Sciences, University of Eastern Finland, Kuopio, Finland.
Petri HyytiäDepartment of Pharmacology, Faculty of Medicine, University of Helsinki, Helsinki, Finland.
Markus M ForsbergSchool of Pharmacy, Faculty of Health Sciences, University of Eastern Finland, Kuopio, Finland.
Esko KankuriDepartment of Pharmacology, Faculty of Medicine, University of Helsinki, Helsinki, Finland.
Esa R KorpiDepartment of Pharmacology, Faculty of Medicine, University of Helsinki, Helsinki, Finland.
University of Helsinki · FIFinland University · FIUniversity of Eastern Finland · FI

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mephedrone (4-MMC), despite its illegal status, is still a widely used psychoactive substance. Its effects closely mimic those of the classical stimulant drug methamphetamine (METH). Recent research suggests that unlike METH, 4-MMC is not neurotoxic on its own. However, the neurotoxic effects of 4-MMC may be precipitated under certain circumstances, such as administration at high ambient temperatures. Common use of 4-MMC in conjunction with alcohol raises the question whether this co-consumption could also precipitate neurotoxicity. A total of six groups of adolescent rats were treated twice daily for four consecutive days with vehicle, METH (5 mg/kg) or 4-MMC (30 mg/kg), with or without ethanol (1.5 g/kg). To investigate persistent delayed effects of the administrations at two weeks after the final treatments, manganese-enhanced magnetic resonance imaging brain scans were performed. Following the scans, brains were collected for Golgi staining and spine analysis. 4-MMC alone had only subtle effects on neuronal activity. When administered with ethanol, it produced a widespread pattern of deactivation, similar to what was seen with METH-treated rats. These effects were most profound in brain regions which are known to have high dopamine and serotonin activities including hippocampus, nucleus accumbens and caudate-putamen. In the regions showing the strongest activation changes, no morphological changes were observed in spine analysis. By itself 4-MMC showed few long-term effects. However, when co-administered with ethanol, the apparent functional adaptations were profound and comparable to those of neurotoxic METH.

Indexed as

co-consumptionethanolgolgi-stainingMEMRImephedronemethamphetaminestimulant

Identifiers

PMID33995109
PMCPMC8115874
OpenAlexW3158184114

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.